CRISPR Therapeutics – Corporate Update To Jump Start 2018
Company is powering a robust portfolio of gene-editing and CAR-T to service the orphan diseases market.
Dr. Novak recently transitioned to his new post as Chairman of the Board.
This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.
As one of the stocks that transitioned into 2018 strong, the share price of CRISPR Therapeutics (NASDAQ:CRSP), a firm that focuses on gene-editing and CAR-T to treat cancers and genetic diseases, rallied over the 10% during the Dec. 29, 2017 trading session. The stock increased by $2.23 to close out at $23.48. Since we recommended the stock at $19.55 on Nov. 27, 2017, it has now gained $5.62 for 29% profits for subscribers of Integrated BioSci Investing. The recent share price appreciation is partly due to the appointmentof Dr. Rodger Novak, founder and former CEO, into his new role as Chairman of the Board (on Dec. 21, 2017).